Liver neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
We show that MYC overexpression (MYC<sup>Tg</sup>) synergizes with KRAS<sup>G12D</sup> to induce an aggressive liver tumor leading to metastasis formation and reduced mouse survival compared with KRAS<sup>G12D</sup> alone.
|
30643286 |
2019 |
Liver neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
MiR-198 inhibited cancer by suppressing the expression of MYC in liver neoplasm.
|
30378283 |
2018 |
Liver neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
To determine if genetic loss of SRC-2 is sufficient to accelerate MYC-mediated liver tumorigenesis, we bred Src-2-/- mice with a MYC-induced liver tumor model and observed a significant increase in liver tumor burden.
|
28273073 |
2017 |
Liver neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
C57BL/6 mice received hydrodynamic tail-vein injections of transposons encoding HRAS<sup>G12V</sup> and a short hairpin RNA (shRNA) to down-regulate p53, or those encoding HRAS<sup>G12V</sup> and MYC, or those encoding HRAS<sup>G12V</sup> and TAZ<sup>S89A</sup>, to induce liver tumor formation; mice were also given injections of transposons encoding SMAD7 or shRNA against SMAD2, SMAD3, SMAD4, or SNAI1 (Snail), with or without ectopic expression of Snail.
|
28734833 |
2017 |
Liver neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Finally, MYC-driven liver tumors exhibit increased sensitivity to acute oxidative stress.
|
28219903 |
2017 |
Liver neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Overexpression of IGF2 accelerates formation of liver tumors in mice with hepatic expression of MYC and AKT1, via activation of IGF1 receptor signaling.
|
27614046 |
2016 |
Liver neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Identification of MYC-Dependent Transcriptional Programs in Oncogene-Addicted Liver Tumors.
|
27197165 |
2016 |
Liver neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Our results establish CDK9 inhibition as a therapeutic strategy for MYC-overexpressing liver tumors and highlight the relevance of transcription elongation in the addiction of cancer cells to MYC.
|
25128497 |
2014 |
Liver neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Finally, we found that a small Myc target gene set of 16 genes could be used to identify liver tumors due to Myc upregulation.
|
23038063 |
2013 |
Liver neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Increased glutamine catabolism in MYC-induced liver tumors is associated with decreased levels of glutamine synthetase (Glul) and the switch from Gls2 to Gls1 glutaminase.
|
22326218 |
2012 |
Liver neoplasms
|
0.600 |
Biomarker
|
group |
RGD |
Mechanistic study on liver tumor promoting effects of flutamide in rats.
|
22076107 |
2012 |
Liver neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Our results suggest that continued upregulation of c-Myc target genes promotes the liver tumor formation after about 1 year of age.
|
22182413 |
2012 |
Liver neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Treatment of the human hepatoma cell line HepG2 with hepatic growth factor (Hgf) caused c-Myc protein induction and transcriptional up-regulation of candidate genes, albeit at different levels when individual genes were compared.
|
22653869 |
2012 |
Liver neoplasms
|
0.600 |
Therapeutic
|
group |
RGD |
Antioxidant N-acetyl-L-cysteine (NAC) supplementation reduces reactive oxygen species (ROS)-mediated hepatocellular tumor promotion of indole-3-carbinol (I3C) in rats.
|
22129741 |
2011 |
Liver neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
We found that RB inactivation has minimal effects on the cell cycle, cell death, and differentiation features of liver tumors driven by increased levels of c-MYC.
|
21573126 |
2011 |
Liver neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The molecular profile of the HCV-associated HCC confirmed central roles for MYC and TGFbeta1 in liver tumor development.
|
20380719 |
2010 |
Liver neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
|
18722373 |
2008 |
Liver neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer.
|
19061838 |
2008 |
Liver neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Consistent with the recently reported association between c-MYC overexpression and induction of telomerase activity, we find here that GA treatment of a human hepatoma cell line SMMC-7721 significantly reduced the expression of c-MYC in a time- and concentration-dependent manner accompanied with the down-regulation of the hTERT transcription and the ultimate reduction in telomerase activity.
|
16257012 |
2006 |
Liver neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Hence, chloroform prevented the hypomethylation and increased mRNA expression of the c-myc gene and the promotion of liver tumors by DCA, while enhancing DCA-promotion of kidney tumors.
|
11532874 |
2001 |
Liver neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Transgenic mouse models in carcinogenesis: interaction of c-myc with transforming growth factor alpha and hepatocyte growth factor in hepatocarcinogenesis.
|
8807143 |
1996 |
Liver neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
The expression of the c-myc gene has previously been shown to be elevated and deregulated in the human hepatoma cell line Hep G2 (B. E. Huber and S. S. Thorgeirsson, Cancer Res., 47: 3414-3420, 1987).
|
2154325 |
1990 |
Liver neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Expression of c-myc gene in human hepatoma.
|
2415125 |
1985 |
Liver neoplasms
|
0.600 |
Biomarker
|
group |
MGD |
|
|
|